Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

(2021) Larissa A. Korde et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

(2021) Andrés Poveda et al.   LANCET ONCOLOGY

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

(2021) Andrew N.J. Tutt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

(2020) Ghulam Rehman Mohyuddin et al.   BMC CANCER

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer

(2020) Ke-Da Yu et al.   JAMA Oncology

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Véronique Diéras et al.   LANCET ONCOLOGY

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

(2020) Priyanka Sharma et al.   CLINICAL CANCER RESEARCH

Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum

(2020) Rebecca Dent et al.   LANCET ONCOLOGY

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

(2020) Pierre-Marie Morice et al.   Lancet Haematology

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

(2019) G Curigliano et al.   ANNALS OF ONCOLOGY

CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

(2019) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).

(2019) Priyanka Sharma et al.   JOURNAL OF CLINICAL ONCOLOGY

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

(2018) Peter A. Fasching et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States

(2018) Rahul Shenolikar et al.   GYNECOLOGIC ONCOLOGY

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

(2018) S Loibl et al.   ANNALS OF ONCOLOGY

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

(2017) Norikazu Masuda et al.   NEW ENGLAND JOURNAL OF MEDICINE

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer

(2017) Tithi Biswas et al.   Oncotarget

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

(2017) Eric Hahnen et al.   JAMA Oncology

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

(2016) E. T. Rodler et al.   CLINICAL CANCER RESEARCH

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

(2016) Hope S. Rugo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Profile of veliparib and its potential in the treatment of solid tumors

(2015) Lars Wagner   OncoTargets and Therapy

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

(2014) Stefan Aebi et al.   LANCET ONCOLOGY